Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$4.34 CAD
Change Today -0.27 / -5.86%
Volume 28.9K
I On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ CM
Frankfurt
As of 3:59 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

intellipharmaceutics interna (I) Snapshot

Open
C$4.50
Previous Close
C$4.61
Day High
C$4.50
Day Low
C$4.34
52 Week High
07/15/15 - C$4.99
52 Week Low
08/27/14 - C$2.14
Market Cap
103.7M
Average Volume 10 Days
38.7K
EPS TTM
C$-0.22
Shares Outstanding
23.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTELLIPHARMACEUTICS INTERNA (I)

Related News

No related news articles were found.

intellipharmaceutics interna (I) Related Businessweek News

No Related Businessweek News Found

intellipharmaceutics interna (I) Details

Intellipharmaceutics International Inc., a pharmaceutical company, engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs in Canada. The company develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, such as neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. Its products under abbreviated new drug application stage include Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorders; Effexor XR, a venlafaxine hydrochloride extended-release capsule for depression; Protonix, a tablet for gastroesophageal reflux diseases; Glucophage XR, a tablet for managing type 2 diabetes; Seroquel XR, a tablet for the treatment of schizophrenia, as well as bipolar and depressive disorders; Lamictal XR, a tablet for anti-convulsant for epilepsy; Keppra XR, a tablet for the treatment of partial onset seizures for epilepsy; and Pristiq, a tablet for depression. The company is also developing Oleptro, a trazodone hydrochloride extended release tablet for treating depression; Coreg CR, a capsule, which is in late-stage development for heart failure and hypertension; OxyContin, a controlled release capsule that is in phase I clinical trial for pain; and Lyrica, a capsule, which is in phase I clinical trial for neuropathic pain. Its non-generic products under development include Rexista, an oral formulation for pain relief; and Regabati XR, a pregabalin extended release capsule that has completed an initial phase I clinical trial for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury, and fibromyalgia. The company has a license and commercialization agreement with Par Pharmaceutical, Inc. Intellipharmaceutics International Inc. is headquartered in Toronto, Canada.

46 Employees
Last Reported Date: 02/27/15

intellipharmaceutics interna (I) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $582.0K
President, Chief Operating Officer and Direct...
Total Annual Compensation: $582.0K
Chief Financial Officer
Total Annual Compensation: $5.2K
Vice President of Legal Affairs & Licensing, ...
Total Annual Compensation: $132.2K
Compensation as of Fiscal Year 2014.

intellipharmaceutics interna (I) Key Developments

Intellipharmaceutics International Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended May 31, 2015

Intellipharmaceutics International Inc. announced unaudited consolidated earnings results for the second quarter and six months ended May 31, 2015. For the quarter, the company revenue was $1,268,245 compared with $1,478,942 a year ago. Loss from operations was $1,378,014 compared to $3,065,625 a year ago. Net loss and comprehensive loss was $1,507,270 or $0.06 basic and diluted per share compared to $3,140,275 or $0.14 basic and diluted per share a year ago. Cash flow used in operating activities was $1,150,362 compared with cash flow provided from operating activities of $918,965 a year ago. Purchase of property and equipment was $153,894 compared with $217,319 a year ago. The net loss for the three months ended May 31, 2015, is lower than the comparable prior period primarily due to reduced stock-based compensation and bonus expense, and tighter overall cost control. For the six months, the company revenue was $2,407,930 compared with $6,160,000 a year ago. Loss from operations was $2,225,280 compared to $820,337 a year ago. Net loss and comprehensive loss was $2,421,930 or $0.10 basic and diluted per share compared to $938,840 or $0.04 basic and diluted per share a year ago. Cash flow used in operating activities was $1,277,909 compared with cash flow provided from operating activities of $1,136,089 a year ago. Purchase of property and equipment was $185,387 compared with $282,879 a year ago.

IntelliPharmaCeutics International Inc. to Report Q2, 2015 Results on Jul 13, 2015

IntelliPharmaCeutics International Inc. announced that they will report Q2, 2015 results on Jul 13, 2015

Intellipharmaceutics Updates Status of Tentative Approvals of Generic Focalin XR

Intellipharmaceutics International Inc. announced that the United States Food and Drug Administration has indicated to the Company that it has rescinded its previous requirement that the Company meet newly-imposed conditions for bioequivalence prior to receiving final approval for the company's tentatively-approved strengths of its generic Focalin XR® (dexmethylphenidate hydrochloride extended-release) capsules. The strengths affected include 5 mg, 10 mg, 20 mg and 40 mg. The already-approved 15 mg and 30 mg strengths now in the market are not affected.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
I:CN C$4.34 CAD -0.27

I Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Durect Corp $2.35 USD -0.04
Lupin Ltd 1,697 INR 0.00
Torrent Pharmaceuticals Ltd 1,442 INR 0.00
View Industry Companies
 

Industry Analysis

I

Industry Average

Valuation I Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.6x
Price/Book 26.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTELLIPHARMACEUTICS INTERNA, please visit www.intellipharmaceutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.